Dihexa Peptide Research: HGF/c-Met Neurotrophic Signaling, Picomolar Synaptogenic Potency, and Preclinical Cognitive Evidence

Dihexa peptide research has attracted significant attention in the neuroscience community due to its extraordinary potency as an activator of the hepatocyte growth factor (HGF)/c-Met signaling system. Developed at Washington State University by the Harding laboratory, dihexa (PNB-0408) is a metabolically stabilized angiotensin IV derivative that demonstrates synaptogenic activity at concentrations seven orders of magnitude (approximately 10 million-fold) lower than brain-derived neurotrophic factor (BDNF). For Canadian researchers investigating neurotrophic signaling, synaptic plasticity, or cognitive neuropharmacology, dihexa represents a structurally unique research tool. Research-grade peptides with verified purity documentation are available from Maple Research Labs.

Chemical Structure and Molecular Properties

Dihexa (CAS 1401708-83-5) has the molecular formula C₂₇H₄₄N₄O₅ and a molecular weight of 504.66 g/mol. Structurally, it is classified as a modified hexapeptide derivative, though its small size places it at the boundary between peptide and peptidomimetic compounds. The systematic name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide.

The compound was engineered through strategic modifications of Nle1-angiotensin IV (Nle1-AngIV), a metabolically stabilized form of angiotensin IV. Three structural changes define dihexa’s pharmacological profile: the N-terminal valine is replaced with a hexanoyl (N-hexanoic acid) cap to improve metabolic stability and membrane permeability, the core Tyr-Ile pharmacophore is retained as the minimum binding motif for HGF interaction, and the C-terminal His-Pro-Phe tripeptide is substituted with a 6-aminohexanoic amide moiety. These modifications produce a compact, orally bioavailable molecule that crosses the blood-brain barrier while retaining the neurotrophic signaling properties of the parent angiotensin IV system.

Mechanism of Action: HGF/c-Met Pathway Activation

Dihexa’s primary mechanism operates through the hepatocyte growth factor (HGF) and its tyrosine kinase receptor, c-Met. Unlike direct receptor agonists, dihexa functions as an allosteric potentiator of HGF signaling. The compound binds to HGF with remarkably high affinity, demonstrating a dissociation constant (K_d) of approximately 65 picomolar (pM). This binding stabilizes HGF in an active conformation, enhancing its ability to engage and activate c-Met at subthreshold concentrations that would otherwise be insufficient for receptor phosphorylation.

Upon c-Met activation, dihexa triggers a well-characterized intracellular signaling cascade. Phosphorylation of c-Met initiates downstream activation of the PI3K/Akt and Ras/MAPK pathways, which in hippocampal neurons drives spinogenesis (new dendritic spine formation), synaptogenesis (new synaptic connection establishment), enhanced synaptic density in brain regions associated with learning and memory consolidation, support for neural stem cell proliferation and differentiation, and reduction of neuroinflammatory signaling through modulation of microglial activation states.

This mechanism is fundamentally distinct from other neurotrophic research compounds. While BPC-157 acts primarily through VEGFR2-mediated angiogenic and cytoprotective pathways, and Selank modulates GABAergic and immunomodulatory systems, dihexa’s engagement of the HGF/c-Met axis targets a growth factor system with documented roles in both developmental neurogenesis and adult synaptic remodeling.

Key Research Findings: Preclinical Cognitive Data

The foundational preclinical dataset for dihexa comes from the Harding laboratory at Washington State University, published across several peer-reviewed studies that established the compound’s neurotrophic profile.

McCoy et al. (2013), Journal of Pharmacology and Experimental Therapeutics, 344(1):141-54: This seminal study evaluated dihexa as a metabolically stabilized angiotensin IV analog with procognitive activity. In scopolamine-induced cognitive deficit models in rats, oral administration of dihexa at 2 mg/kg fully reversed cognitive impairment by day 7 of treatment. Performance in treated animals was statistically indistinguishable from untreated controls, demonstrating both oral bioavailability and blood-brain barrier penetration. The study confirmed that dihexa’s procognitive effects are mediated through the central HGF/c-Met system, as co-administration of HGF pathway inhibitors abolished the cognitive rescue.

Benoist et al. (2014), Journal of Pharmacology and Experimental Therapeutics: This follow-up study provided direct evidence that dihexa’s cognitive effects are dependent on HGF/c-Met activation. Both dihexa and its parent compound Nle1-AngIV induced c-Met phosphorylation in the presence of subthreshold HGF concentrations and augmented HGF-dependent cell scattering in in vitro assays. Critically, both compounds induced hippocampal spinogenesis and synaptogenesis at activity levels comparable to HGF itself, producing a near 3-fold increase in dendritic spine density in cultured hippocampal neurons at picomolar concentrations.

Potency comparison with BDNF: The research team reported that dihexa produced new neuronal connections in cell culture assays at concentrations seven orders of magnitude (10⁷-fold) lower than those required for brain-derived neurotrophic factor (BDNF) to achieve comparable synaptogenic effects. To contextualize this, where BDNF might require nanomolar concentrations for spine induction, dihexa achieves similar outcomes in the femtomolar to picomolar range. This extraordinary potency differential makes dihexa a uniquely valuable research tool for studying the minimum signaling thresholds required for synaptic remodeling.

Angiotensin IV System Context and Research Implications

Dihexa’s development emerged from decades of research into the brain renin-angiotensin system (RAS), which extends well beyond cardiovascular regulation. Angiotensin IV (AngIV), the endogenous peptide from which dihexa derives, signals through the AT4 receptor, which was subsequently identified as insulin-regulated aminopeptidase (IRAP). However, the Harding laboratory’s work demonstrated that the procognitive effects of AngIV analogs are not mediated through IRAP binding but rather through the HGF/c-Met system, a finding that fundamentally reoriented the field’s understanding of how angiotensin-derived peptides affect cognition.

This mechanistic clarification has important implications for researchers studying neuropeptide pharmacology. It demonstrates that small peptide modifications can redirect signaling from one receptor system (IRAP) to an entirely different growth factor pathway (HGF/c-Met), a principle relevant to the broader peptide design field. Researchers working with other angiotensin-derived compounds or investigating research peptides targeting neurotrophic pathways should consider this precedent when interpreting receptor binding and functional data.

Comparison with Other Neurotrophic Research Peptides

Positioning dihexa within the broader landscape of neurotrophic peptide research helps clarify its unique pharmacological niche. Semax, an ACTH(4-10) analog, exerts neurotrophic effects through BDNF upregulation and TrkB receptor signaling, operating at micromolar effective concentrations. Selank, a tuftsin-derived peptide, modulates cognitive function through GABAergic modulation and enkephalin system interactions. GHK-Cu, a copper-binding tripeptide, influences gene expression patterns relevant to neuroregeneration but acts through a metal ion coordination mechanism rather than growth factor potentiation.

Dihexa’s picomolar potency through HGF/c-Met activation represents a mechanistically orthogonal approach to each of these compounds. For researchers designing multi-target neurotrophic studies, dihexa’s distinct signaling pathway (HGF/c-Met vs. BDNF/TrkB vs. GABAergic modulation) makes it a useful comparator that can help isolate the contribution of specific neurotrophic pathways to cognitive and synaptic outcomes.

Analytical Verification and Research Material Quality

Dihexa’s picomolar activity range demands exceptional purity in research materials, as even trace impurities at conventional peptide concentrations could introduce confounding biological activity at dihexa’s effective dose range. HPLC purity verification to ≥99% and mass spectrometric identity confirmation are minimum analytical requirements. Maple Research Labs provides independent third-party COA verification through Janoshik Analytical, ensuring that batch-specific purity data accompanies every research shipment.

Storage of lyophilized dihexa should maintain the compound at -20°C in a desiccated environment. Reconstituted solutions should be aliquoted to minimize freeze-thaw cycles and stored at 2-8°C for short-term use. Researchers should consult handling documentation for detailed reconstitution and stability guidance.

Research Summary

• Dihexa (PNB-0408, CAS 1401708-83-5) is a modified angiotensin IV derivative with the molecular formula C₂₇H₄₄N₄O₅ and a molecular weight of 504.66 g/mol
• Binds hepatocyte growth factor (HGF) with K_d ≈ 65 pM, potentiating c-Met receptor activation and downstream PI3K/Akt and Ras/MAPK signaling
• Demonstrates synaptogenic activity 10⁷-fold (seven orders of magnitude) more potent than BDNF in hippocampal neuron culture assays
• Produces a near 3-fold increase in dendritic spine density in hippocampal neurons at picomolar concentrations (Benoist et al., 2014)
• Oral dihexa at 2 mg/kg fully reversed scopolamine-induced cognitive deficits in rat models by day 7, confirming oral bioavailability and BBB penetration (McCoy et al., 2013)
• Mechanism is HGF/c-Met dependent, not IRAP-mediated, distinguishing it from other angiotensin-derived peptides

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

For peer-reviewed research on this topic, visit PubMed.